3-(氨基甲基)-2-叔丁氧基吡啶 | 849021-22-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-(氨基甲基)-2-叔丁氧基吡啶
• 中文别名: 2-(叔丁氧基)-3-(氨甲基)吡啶
• 英文名称: 3-(Aminomethyl)-2-tert-butoxypyridine
• 英文别名: [2-[(2-methylpropan-2-yl)oxy]pyridin-3-yl]methanamine
• CAS: 849021-22-3
• 化学式: C₁₀H₁₆N₂O
• 分子量: 180.25
• InChiKey: YASWEPDVXCKCPE-UHFFFAOYSA-N

物化性质

• 沸点：
  52～54℃/0.05mm

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

文献信息

• [EN] SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS PYRAZOLE SUBSTITUÉS ET LEUR UTILISATION
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009119880A1

  公开（公告）日：2009-10-01

  The present invention aims to provide a pyrazole derivative represented by the formula (I') or a salt thereof.

  本发明旨在提供由式(I')表示的吡唑衍生物或其盐。
• Substituted pyrazole derivatives and use thereof
  申请人：Ito Mitsuhiro

  公开号：US20090270361A1

  公开（公告）日：2009-10-29

  The present invention aims to provide a novel pyrazole derivative and a pharmaceutical agent containing the same. The present invention provides a compound represented by the formula (I′) wherein R 1 ′ is (1) a hydrogen atom, (2) a group via a carbon atom, (3) a group via a nitrogen atom, (4) a group via an oxygen atom or (5) a group via a sulfur atom; R 2 ′ is an aromatic ring group optionally having substituent(s); R 3 ′ is (1) a hydrogen atom, (2) a group via a carbon atom, (3) a group via a nitrogen atom, (4) a group via an oxygen atom or (5) a group via a sulfur atom; R 4 ′ is a cyanophenyl group optionally having substituent(s); X′ is (1) —Y′—CR 5 ′R 6 ′-Z′- wherein R 5 ′ and R 6 ′ are the same or different and each is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom or a group via a sulfur atom, or —CR 5 ′R 6 ′— is —C(alkylidene)-; Y′ is a bond, —COCO—, —CONH—, —COCONH— or —O—; and Z′ is a bond, —CH 2 —, —CONH—, —O—, —OCH 2 —, —S—, —SO—, —SO 2 —, —CON(C 6 H 5 )— or (2) —CO(CONH) n — wherein n is 0 or 1, (3) —NHCO—, (4) —CONH—, (5) —O—, (6) —CH═CH— or (7) —O(C 1-3 alkylene)O—; (excluding the compounds indicated to be excluded from the specification), or a salt thereof.

  本发明旨在提供一种新型吡唑衍生物及其制备的药物。本发明提供一种化合物，其表示为公式（I'）： 其中，R1'是（1）氢原子，（2）通过碳原子的基团，（3）通过氮原子的基团，（4）通过氧原子的基团或（5）通过硫原子的基团；R2'是芳香环基团，可选地具有取代基；R3'是（1）氢原子，（2）通过碳原子的基团，（3）通过氮原子的基团，（4）通过氧原子的基团或（5）通过硫原子的基团；R4'是氰基苯基团，可选地具有取代基；X'是（1）-Y'-CR5'R6'-Z'-，其中R5'和R6'相同或不同，每个都是氢原子，通过碳原子的基团，通过氮原子的基团，通过氧原子的基团或通过硫原子的基团，或者-CR5'R6'-是-C（烷基亚基）-；Y'是键，-COCO-，-CONH-，-COCONH-或-O-；Z'是键，-CH2-，-CONH-，-O-，-O -，-S-，-SO-，-SO2-，-CON（C6H5）-或（2）-CO（CONH）n-，其中n为0或1，（3）-NHCO-，（4）-CONH-，（5）-O-，（6）-CH═CH-或（7）-O（C1-3烷基亚基）O-；（不包括规范中指定要排除的化合物）或其盐。
• Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors
  申请人：ALLEN David George

  公开号：US20080175914A1

  公开（公告）日：2008-07-24

  The invention relates to a compound of formula (I) or a salt thereof: wherein: R 1 is C 1-4 alkyl, C 1-3 fluoroalkyl, —CH 2 CH 2 OH or —CH 2 CH 2 CO 2 C 1-2 alkyl; R 2 is a hydrogen atom (H), methyl or C 1 fluoroalkyl; R 3 is optionally substituted C 3-8 cycloalkyl or optionally substituted mono-unsaturated-C 5-7 cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n 1 and n 2 independently are 1 or 2; and in which Y is O, S, SO 2 , or NR 10 ; or R 3 is a bicyclic group (dd) or (ee): and wherein X is NR 4 R 5 or OR 5a . The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE 4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

  本发明涉及公式（I）的化合物或其盐： 其中： R1是C1-4烷基，C1-3氟烷基，-CH2CH2OH或-CH2CH2CO2C1-2烷基; R2是氢原子（H），甲基或C1氟烷基; R3是可选取代的C3-8环烷基或可选取代的单不饱和C5-7环烯基或亚公式（aa），（bb）或（cc）的可选取代的杂环基; 其中n1和n2独立地为1或2; Y是O，S，SO2或NR10; 或R3是双环基（dd）或（ee）： 其中X是NR4R5或OR5a。 该化合物是磷酸二酯酶（PDE）抑制剂，特别是PDE4抑制剂。本发明还提供了公式（I）的化合物或其药学上可接受的盐的用途，用于制造治疗和/或预防哺乳动物，如人类的炎症性和/或过敏性疾病的药物，例如慢性阻塞性肺疾病（COPD），哮喘或过敏性鼻炎。
• Ferroportin inhibitors
  申请人：Vifor (International) AG

  公开号：US10364239B2

  公开（公告）日：2019-07-30

  The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

  本发明涉及通式(A-I)的新型化合物，其中Het-2为通式(AA)的任选取代的双环杂芳基。本发明涉及由这些化合物组成的药物组合物及其作为药物的用途，特别是作为铁皮质素抑制剂的用途，尤其是用于预防和/或治疗由缺乏铁皮质素或铁代谢紊乱引起的疾病，如特别是铁过载状态，如地中海贫血症和血色病。
• FERROPORTIN INHIBITORS
  申请人：Vifor (International) AG

  公开号：EP3364967A2

  公开（公告）日：2018-08-29